NCT04662281Phase 2Completed

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-11-18Actual

Enrollment · participants79Actual

Source updated2026-02-13Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-11-25 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Change ~~from~~ Baseline in Average Daily Pain Score (ADPS)

+ After

Measure: Change From Baseline (Week 2 of the Run-in Period) in Average Daily Pain Score (ADPS)

Check registry source

Study details

Conditions studied

Postherpetic Neuralgia

Treatments or interventions studied

PlaceboDrug
LX9211Drug

Primary outcomes · main study measures

Read the study measures

measure: Change From Baseline (Week 2 of the Run-in Period) in Average Daily Pain Score (ADPS); description: ADPS is based on question 5 of Zoster Brief Pain Inventory (ZBPI) and assessed on an 11-point numerical rating scale where, 0 = No Pain to 10 = pain as bad as you can imagine. Higher ADPS scores indicates a worse outcome. Negative change from baseline indicates no pain.; timeFrame: Baseline (Week 2 of the Run-in period) to Week 6

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history